181 related articles for article (PubMed ID: 30856121)
1. Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report.
Radder DLM; Tiel Groenestege AT; Boers I; Muilwijk EW; Bloem BR
J Parkinsons Dis; 2019; 9(2):437-439. PubMed ID: 30856121
[TBL] [Abstract][Full Text] [Related]
2. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
[TBL] [Abstract][Full Text] [Related]
3. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480
[TBL] [Abstract][Full Text] [Related]
4. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G
Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722
[TBL] [Abstract][Full Text] [Related]
5. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
[TBL] [Abstract][Full Text] [Related]
6.
Cilia R; Laguna J; Cassani E; Cereda E; Pozzi NG; Isaias IU; Contin M; Barichella M; Pezzoli G
Neurology; 2017 Aug; 89(5):432-438. PubMed ID: 28679598
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206
[TBL] [Abstract][Full Text] [Related]
8. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
[TBL] [Abstract][Full Text] [Related]
9. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
10. Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?
Fothergill-Misbah N; Maroo H; Cham M; Pezzoli G; Walker R; Cilia R
Parkinsonism Relat Disord; 2020 Apr; 73():3-7. PubMed ID: 32179240
[TBL] [Abstract][Full Text] [Related]
11.
Kamkaen N; Chittasupho C; Vorarat S; Tadtong S; Phrompittayarat W; Okonogi S; Kwankhao P
Molecules; 2022 May; 27(10):. PubMed ID: 35630617
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Battistin L; Meneghetti G; Rigotti S; Saia A
Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-Reduced
Johnson SL; Park HY; DaSilva NA; Vattem DA; Ma H; Seeram NP
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30131460
[No Abstract] [Full Text] [Related]
14. Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice.
Caronni S; Del Sorbo F; Barichella M; Fothergill-Misbah N; Denne T; Laguna J; Urasa S; Dekker MCJ; Akpalu A; Sarfo FS; Cham M; Pezzoli G; Cilia R
Parkinsonism Relat Disord; 2024 Jul; 124():106983. PubMed ID: 38797572
[TBL] [Abstract][Full Text] [Related]
15. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
16. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
Sweet RD; McDowell FH; Wasterlain CG; Stern PH
Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
Marsden CD; Barry PE; Parkes JD; Zilkha KJ
J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682
[TBL] [Abstract][Full Text] [Related]
18. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Lieu CA; Kunselman AR; Manyam BV; Venkiteswaran K; Subramanian T
Parkinsonism Relat Disord; 2010 Aug; 16(7):458-65. PubMed ID: 20570206
[TBL] [Abstract][Full Text] [Related]
19. Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures.
Pathak-Gandhi N; Vaidya AD
J Ethnopharmacol; 2017 Feb; 197():46-51. PubMed ID: 27544001
[TBL] [Abstract][Full Text] [Related]
20. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
